Search Articles — Sudonull

https://sudonull.com/hp-eliteboard-g1a-keyboard-pc-with-amd-ryzen-ai

HP EliteBoard G1a — a full-fledged PC in a keyboard with AMD Ryzen AI and 50 TOPS. Desktop mobility for hybrid work. Find out the price and specifications.

https://sudonull.com/hwmonitor-1-63-new-intel-and-amd

HWMonitor 1.63 update adds support for Intel Arrow Lake, AMD Ryzen AI and Arc GPU. Sensor monitoring for Windows. Download for hardware tests — accurate data without overhead.

https://sudonull.com/fsr-4-1-on-old-amd-cards-a-forced-decision

AMD adds FSR 4.1 to RX 7000 and 6000, but this is not generosity, but capitulation to NVIDIA and modders. Find out why your GPU's lifespan will be extended, but the victory remains with the community.

https://sudonull.com/amd-helios-vs-nvidia-war-for-ai-racks

AMD launches Helios — an open AI rack against Nvidia. Find out why this is a data center market reshuffle, not just a new chip. Analytics and forecasts.

https://sudonull.com/amd-to-invest-10-billion-in-2nm-chips-in-taiwan-strategy-vs-nvidia

AMD invests $10 billion in production of 2nm EPYC Venice processors in Taiwan. Analysis of the race with NVIDIA, EFB technology and forecasts. Read details.

https://ymaho.com/fda-approved-the-first-ophthalmic-bevacizumab-lytenava-for-the-treatment-of-wet-amd

FDA accepted Outlook Therapeutics' appeal and will approve LYTENAVA — a standardized bevacizumab for neovascular AMD. Analysis of consequences for the anti-VEGF market, pricing, and patients. Read more.

https://ymaho.com/fda-may-approve-ophthalmic-bevacizumab-lytenava

Analysis of the regulatory paradox: why the FDA rejected it three times, while Europe approved it. Learn how the Lytenava decision will change the $16 billion AMD market.

https://ymaho.com/purchase-of-intel-citadel-ken-griffin-s-bet-on-12-million-shares

Ken Griffin's Citadel bought 12 million Intel (INTC) shares and reduced its stake in AMD. Analysis of the 13F report, hidden factors, and forecasts. Read more.